Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... Stage Product Targeting Life-threatening Hereditary ... to Host Conference Call at 10:30 A.M. Eastern Today to Discuss ... ... Incorporated,(Nasdaq: VPHM ) and Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP),today ...
... July 15 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin ... firm specializing in the manufacture,research, development, marketing ... appointment of American Stock Transfer & Trust ... registrar, effective August 15, 2008.,AST, headquartered in ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... results will be released on,Thursday, July 31, 2008. The ... 10:00 a.m. Eastern Time, July 31, 2008, to discuss ... by Steven G.,Anderson, president and CEO of CryoLife, Inc., ...
Cached Biology Technology:ViroPharma To Acquire Lev Pharmaceuticals 2ViroPharma To Acquire Lev Pharmaceuticals 3ViroPharma To Acquire Lev Pharmaceuticals 4ViroPharma To Acquire Lev Pharmaceuticals 5ViroPharma To Acquire Lev Pharmaceuticals 6ViroPharma To Acquire Lev Pharmaceuticals 7ViroPharma To Acquire Lev Pharmaceuticals 8ViroPharma To Acquire Lev Pharmaceuticals 9China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008 2CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:7/25/2014)... central nervous system disease that is caused by ... the embryonic phase. Many patients have varying degrees ... retardation. Such problems decrease the patients, functional independence ... Physical Medicine and Rehabilitation Education and Research Hospital, ... SB, using the Pediatric Evaluation of Disability Inventory ...
(Date:7/25/2014)... researchers have detected an unknown interaction between microorganisms and ... into a droplet of salt water and is left ... create biomineralogical biosaline 3D morphologically complex formations, where they ... revived. The discovery was made by chance with a ... Astrobiology journal and may help to find ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... Studies show the incidence of diabetes in dogs has increased ... Missouri veterinarians have changed the way veterinarians treat diabetes in ... humans. Dogs are susceptible to type 1, insulin-dependent diabetes. ... because their bodies do not produce enough insulin, a hormone ...
... around the world have forced many species to the brink ... multiple causes that are still not fully understood, researchers conclude ... causative factor is often missing the larger picture, they said, ... don,t consider the totality of causes or could even ...
... April 25, 2011 - Call them the Jason Bournes of ... secret agents, some bacteria avoid antibiotic treatments by essentially shutting ... says Thomas Wood, professor in the Artie McFerrin Department of ... elaborate survival mechanism is explained in the online April edition ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3